03:32 AM EDT, 04/27/2026 (MT Newswires) -- Astrazeneca (AZN) said Monday its Saphnelo Pen has been approved in the US as a once-weekly self-administered subcutaneous treatment of adult patients with systemic lupus erythematosus in addition to standard therapy.

The US Food and Drug Administration's approved was based on results from a phase 3 trial showing the treatment led to a "statistically significant and clinically meaningful"reduction in disease activity compared to placebo in patients with moderate to severe systemic lupus erythematosus while receiving standard therapy, the company said.